About Rene Verkaart

This author has not yet filled in any details.
So far Rene Verkaart has created 8 blog entries.

Softhale certified to ISO 13485: 2016

By |2021-08-12T12:12:10+00:00July 12th, 2021|

Softhale has successfully achieved certification of its’ quality management system for medical devices. ISO 13485 is the medical industry's optimal, internationally agreed, medical device standard. It ensures that medical devices meet the proper regulatory compliance laws and customer needs.

A series B fund raising was successfully closed

By |2020-11-18T15:21:08+00:00March 1st, 2019|

A series B fund raising was successfully closed with existing investors led by New Rhein Healthcare Investors LLC in a low double digit mEUR range. The funds will finance near-term R&D activities for our lead compounds entering into the clinic, the growth of our team and expertise to develop our portfolio of branded high-end products as well as the expansion of our collaborations evaluating the span of our technology platform.

Iain Breakwell joins Softhale NV as Head of Project Management

By |2020-11-19T08:21:22+00:00November 1st, 2018|

Iain has a strong scientific background and significant technical project management experience, leading multiple cross-functional teams in high value, first-to-file opportunities for generic combination drug products in varied inhaled dosage forms. Iain joins Softhale from Teva (formerly Actavis) and is ex-Novartis and ex-Sanofi.

Softhale NV announces New Board Member

By |2020-11-18T15:28:31+00:00October 1st, 2018|

We are delighted to welcome Mr. Nevan Charles Elam, J.D., on our Board. He has a rich background in management, operations, consulting, finance, and corporate law in combination with long term experiences in executive roles in pharmaceutical and medical device companies.

Steven Dudley joins Softhale NV as Head of Development

By |2020-11-18T15:30:08+00:00June 25th, 2018|

Steven is an engineer and an expert in combination product development in the field of orally inhaled drug products for both branded and generic submissions. He brings over 20 years of experience, most recently from Teva (formerly Actavis), PA Consulting, Novartis and IVAX.

Jan-Torsten Tews joins Softhale NV as 
Chief Executive Officer

By |2019-06-13T11:58:28+00:00October 5th, 2017|

Dr. Jan-Torsten Tews joins Softhale NV as CEO. Dr. Tews joins from Sandoz, where he led the Global Respiratory Business of Novartis's Gx Division. Prior to Sandoz, he was Head of Respiratory Europe at Teva Pharmaceuticals and had worked for GlaxoSmithKline, Germany, in a broad range of leadership positions across Marketing, Sales and Health Outcomes. Focused on the treatment of asthma and COPD over 20 years and from different perspectives, Dr. Tews brings a vast experience in development, marketing and sales of inhalation products.

Go to Top